Shilpa Medicare subsidiary partners with mAbTree Biologics

Shilpa Medicare announced that its subsidiary, Shilpa Biologicals Private Limited (SBPL), has entered into a strategic partnership with mAbTree Biologics AG, a Switzerland-based company. The agreement, formalized through a binding term sheet, will focus on the co-development, manufacture, and commercialization of a novel NBE for immuno-oncological applications. SBPL will support development, including clinical studies, and will be the long-term commercial supplier via GMP manufacturing. The partnership also provides mAbTree access to the Indian market and other global markets through Shilpa's network. The collaboration aims to advance therapeutic options, particularly in oncology, and will leverage SBPL's R&D capabilities and bio-manufacturing facility in Dharwad, Karnataka. The move is expected to strengthen SBPL's capabilities in innovative therapies.